EAP vs. OLE vs. Open Label Studies in ALS Research: What’s the Difference?

When exploring ALS trials and experimental treatments, people living with ALS and their families often encounter terms like Expanded Access Program (EAP), Open‑Label Extension (OLE), and Open‑Label Studies. While these sound similar, and all involve access to an investigational drug, each pathway serves a different purpose within clinical development.

Below is a brief overview of what each term means, its purpose, and its key features.

Open‑Label Studies

What it is:
An open‑label study is a clinical trial where both researchers and participants know which treatment is being given. Open-label studies can include placebo groups, but if they do, both the participants and researchers know who is receiving the placebo and who is receiving the active treatment.

Purpose:

• To collect additional information about a treatment's safety, tolerability, and potential effectiveness.
• To evaluate different doses or treatment regimens of the same investigational therapy.
• To gather longer-term data after a blinded trial has ended, often through an open-label extension study.
• To conduct studies where blinding is not practical or appropriate for the research objectives.

Key features:

• Both participants and researchers know which treatment is being administered.
• Follows a structured clinical trial protocol.
• Participants must meet eligibility criteria.
• May be conducted at various stages of a clinical development program, including early-phase studies and open-label extension studies.
• Some open-label studies may provide access to an investigational therapy for participants who are eligible to enroll.

Open‑Label Extension (OLE) Studies

What it is:
An OLE study is a continuation phase of a clinical trial that becomes available after the blinded or placebo‑controlled portion ends.

Purpose:

• Allows participants who completed an earlier trial to continue receiving the investigational treatment.
• For participants who were assigned to placebo during the original study, an open-label extension may provide their first opportunity to receive the investigational therapy.
• Helps researchers collect longer-term safety and efficacy data.

Key features:

• Only available to participants who completed the prior clinical trial.
• Everyone receives the active drug—no placebo.
• Designed primarily for continued data collection, not broad access.
• In ALS, OLE studies are common because ALS is progressive and people living with the disease want uninterrupted access to the treatment after finishing the main trial.

Expanded Access Programs (EAP)

What it is:
An Expanded Access Program (EAP), sometimes called "compassionate use," is a regulatory pathway that allows people with a serious or life-threatening disease to access an investigational treatment outside of a clinical trial. EAPs may be considered when no comparable treatment options exist and participation in a clinical trial is not possible or appropriate.

Purpose:

• To provide access to investigational treatments for patients who cannot participate in a clinical trial due to geography, eligibility requirements, disease progression, or other factors.
• Not intended to replace clinical trials.

Key Features:

• Requires approval from the FDA (or other relevant regulatory authority), as well as appropriate ethics oversight. Sufficient clinical data must be available to support the treatment's potential safety and use in the requested population.
• Typically does not collect the same type of data as a formal clinical trial, although safety reporting is required. There must be sufficient evidence to suggest that the potential benefits may outweigh the risks for the patient population being treated.
• Access-based rather than research-focused.
• Must not interfere with ongoing clinical trials.
• Availability is determined by the treatment sponsor; not all investigational therapies have an Expanded Access Program.
• In ALS, EAPs have become especially important because of the limited treatment options available and the urgent need for access to promising investigational therapies.

Quick Comparison Chart

Why this matters for people living with ALS and their families

ALS can progress quickly, and clinical trials often have narrow eligibility windows. Understanding the differences between these programs helps people with ALS:

• Know which options may be available to them.
• Understand why access is sometimes limited.
• Advocate effectively for themselves with clinicians and clinical trial sponsors.

Each pathway, open‑label studies, OLEs, and EAPs, plays a unique role in balancing safety, scientific rigor, and compassionate access in ALS research.

Understanding these pathways is an important part of navigating ALS research today. As a nonprofit research organization, the ALS Therapy Development Institute (ALS TDI) conducts the rigorous research needed to discover and advance potential therapies—using patient data, disease models, and translational science to move promising ideas into clinical trials and, ultimately, into pathways like these.

What to do next:

• Find clinical trials using the ALS Trial Navigator
• Subscribe to clinical trial updates here
• Learn more about Natural History Studies